Key Research Articles


In this Editors Choice newsletter, I wanted to highlight some of the recent excellent content that is being published in our sister journal, Drug Discovery Today: Technologies. In particular, I wanted to bring to your attention some excellent papers from our Spring 2010 issue, entitled: Mechanistic Pharmacology, New Developments. The Editors for this issue are Alan Wise and Terry Kenakin, two of the most influential names in the field of Mechanistic Pharmacology. The issue covers new developments in the field, with articles from Ye Fang on Label-free receptor assays; Gary K. Smith and Edgar R. Wood on Cell-based assays for kinase drug discovery; from Fabio Gasparri and Arturo Galvani on Image-based high-content reporter assays: limitations and advantages ; from William P. Clarke and Kelly A. Berg on Use of functional assays to detect and quantify functional selectivity; from Laura M. Bohn and Patricia H. McDonald on Seeking ligand bias: assessing GPCR coupling to β-arrestins for drug discovery;   from C. Murga, P. Penela, C. Ribas and F Mayor Jr. on G protein-coupled receptor kinases: Specific phosphorylation of 7TM receptors and beyond; from  Kathleen Börner and Dirk Grimm on Use of small RNAs for therapeutic gene silencing: risk versus benefit; from William P. Janzen, Tim J. Wigle, Jian Jin and Stephen V. Frye on Epigenetics: tools and technologies; from Jose M. Lora, David M. Wilson, Kevin Lee and Christopher G.C. Larminie on Epigenetic control of the immune system: histone demethylation as a target for drug discovery; from Sanam Mustafa, Mohammed Akli Ayoub and Kevin D.G. Pfleger on Uncovering GPCR heteromer-biased ligands and from Magalie Rocheville and Stephen L. Garland on An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs.
Some of these articles are available as free downloads in this newsletter. I’d encourage you to have a look as they are very exciting pieces of work. I’d be really pleased to receive your feedback on the content in this issue; if you have any ideas for really hot topics that you think we could cover in the Drug Discovery Today: Technology series, I’d be very pleased to hear from you.
Best wishes
Dr. SL Carney, Editor, Drug Discovery Today
Steve Carney was born in Liverpool, England studied Biochemistry at Liverpool University, obtaining a BSc.(Hons). He then read for a PhD on the Biochemistry and Pathology of Connective Tissue Diseases in Manchester University. On completion of his PhD he moved to the Kennedy Institute of Rheumatology, London 1, where he worked with Professor Helen Muir FRS on the biochemistry of experimental Osteoarthritis. Later, he joined Eli Lilly and Co. where he stayed for 15 years and held a number of positions in Biology R&D, initially in Connective Tissue, but latterly in Neuroscience. He left Lilly in 2002 to take up his present position as Managing Editor, Drug Discovery Today, at Elsevier. He has authored over 40 peer-reviewed articles, written several book chapters and has held a number of patents.